ABSTRACT Background Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and is associated with familial combined hyperlipidaemia (FCHL). Currently, the invasive liver biopsy is considered as the gold standard for evaluating liver fibrosis (LF); however, liver stiffness measurement (LSM) by transient elastography (TE) trough FibroScan device may be employed to estimate LF noninvasively. The aim of this study was to evaluate the prevalence of NAFLD in FCHL subjects and to analyse LSM with TE to better identify those individuals with a potential risk of liver disease progression. Materials and methods Sixty subjects with FCHL (38 men, 22 women, mean age 46Æ4 ± 10Æ9 years) were included in the study. We studied biochemical parameters including lipid profile, glucose, transaminase and insulin; blood pressure and waist circumference (WC) were measured; BMI and HOMA-index were calculated. Ultrasonography was performed to assess liver steatosis and carotid intima-media thickness (IMT). Liver fibrosis was measured by FibroScan. Results Patients were classified according to have no (group 0: 19%), mild (group 1: 32%) or moderate–severe (group 2: 49%) steatosis. No difference was found between group 0 and 1 concerning all study parameters. WC (P < 0Æ05), BMI (P < 0Æ05), glucose (P < 0Æ05), insulin (P < 0Æ001), HOMA-index (P < 0Æ001) and LSM (6Æ03 ± 1Æ9 Kpa vs. 4Æ2 ± 0Æ5 Kpa, P < 0Æ001) were significantly higher in group 2 than groups 1 and 0. Furthermore, LSM correlated with insulin (P < 0Æ05), glucose (P < 0Æ05), HOMA-index (P < 0Æ001), transaminase (P < 0Æ01) and liver steatosis (P < 0Æ001). Regression analysis showed that LSM (P < 0Æ001) and NAFLD (P < 0Æ01) is associated with HOMA-index; NAFLD is also associated with WC (P < 0Æ05). Conclusion Our results suggest that in FCHL subjects, HOMA-index, an insulin resistance index, is strongly associated with liver steatosis and its progression. Furthermore, in these subjects, we propose the transient elastography to identify and follow up patients for the progression of hepatic disease. Keywords Dyslipidaemia, fibroscan, insulin resistance, liver stiffness, metabolic syndrome, NAFLD.

Assessment of liver stiffness in subjects affected by familial combined hyperlipidaemia with hepatic steatosis.

MAMONE, FEDERICA;MANDRAFFINO, GIUSEPPE;MAIMONE, SERGIO;ALIBRANDI, Angela;SAITTA, CARLO;SARDO, Maria Adriana;SQUADRITO, Giovanni;SAITTA, Antonino
2010-01-01

Abstract

ABSTRACT Background Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and is associated with familial combined hyperlipidaemia (FCHL). Currently, the invasive liver biopsy is considered as the gold standard for evaluating liver fibrosis (LF); however, liver stiffness measurement (LSM) by transient elastography (TE) trough FibroScan device may be employed to estimate LF noninvasively. The aim of this study was to evaluate the prevalence of NAFLD in FCHL subjects and to analyse LSM with TE to better identify those individuals with a potential risk of liver disease progression. Materials and methods Sixty subjects with FCHL (38 men, 22 women, mean age 46Æ4 ± 10Æ9 years) were included in the study. We studied biochemical parameters including lipid profile, glucose, transaminase and insulin; blood pressure and waist circumference (WC) were measured; BMI and HOMA-index were calculated. Ultrasonography was performed to assess liver steatosis and carotid intima-media thickness (IMT). Liver fibrosis was measured by FibroScan. Results Patients were classified according to have no (group 0: 19%), mild (group 1: 32%) or moderate–severe (group 2: 49%) steatosis. No difference was found between group 0 and 1 concerning all study parameters. WC (P < 0Æ05), BMI (P < 0Æ05), glucose (P < 0Æ05), insulin (P < 0Æ001), HOMA-index (P < 0Æ001) and LSM (6Æ03 ± 1Æ9 Kpa vs. 4Æ2 ± 0Æ5 Kpa, P < 0Æ001) were significantly higher in group 2 than groups 1 and 0. Furthermore, LSM correlated with insulin (P < 0Æ05), glucose (P < 0Æ05), HOMA-index (P < 0Æ001), transaminase (P < 0Æ01) and liver steatosis (P < 0Æ001). Regression analysis showed that LSM (P < 0Æ001) and NAFLD (P < 0Æ01) is associated with HOMA-index; NAFLD is also associated with WC (P < 0Æ05). Conclusion Our results suggest that in FCHL subjects, HOMA-index, an insulin resistance index, is strongly associated with liver steatosis and its progression. Furthermore, in these subjects, we propose the transient elastography to identify and follow up patients for the progression of hepatic disease. Keywords Dyslipidaemia, fibroscan, insulin resistance, liver stiffness, metabolic syndrome, NAFLD.
2010
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/1903846
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
social impact